Reported Saturday, Madryn Asset Management Urges Institutional Shareholder Services Via Letter To Reconsider 'Cautionary Support' For SomaLogic's Merger With Standard Biotools

Highlights Current Merger Consideration, Which Assigns No Value and No Premium to SomaLogic's Desirable Assets, Represents a Material Discount to Company's Cash

Reiterates Combined Entity's Proforma Capital Structure and Corporate Governance Would Subordinate SomaLogic's Existing Shareholders to Conflicted Insiders, Including Hedge Fund Manager Eli Casdin (a Director of Both Companies)

Underscores SomaLogic has Clearly Identified Value Catalysts and $450+ Million in Cash, Mitigating the Need for a Conflict-Ridden and Rushed Merger That Harms the Company's Common Shareholders